SCHEMBL25967979

SCHEMBL25967979

CSc1ccc(CN2CCN(Cc3ccc(C)cc3)CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.65
▸ LMNA P02545 2/20 0.65
▸ POLB P06746 1/20 0.65
▸ SMN1; SMN2 Q16637 7/20 0.63
▸ MAPT P10636 2/20 0.63
▸ ATM Q13315 3/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ HTT P42858 1/20 0.59
▸ PKM P14618 1/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ NR2F2 P24468 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7989530 0.86 LMNA (0.83) ALDH1A1LMNAPOLBSMN1; SMN2ATM
SCHEMBL1045922 0.86 LMNA (0.83) ALDH1A1LMNAPOLBSMN1; SMN2ATM
SCHEMBL11356824 0.86 LMNA (0.83) ALDH1A1LMNAPOLBSMN1; SMN2ATM
SCHEMBL7989269 0.86 LMNA (0.83) ALDH1A1LMNAPOLBSMN1; SMN2ATM
SCHEMBL17830792 0.85 SMN1; SMN2 (0.71) ALDH1A1LMNAPOLBSMN1; SMN2MAPT
SCHEMBL18131001 0.84 ALDH1A1 (0.66) ALDH1A1LMNASMN1; SMN2MAPTKDM4E
SCHEMBL13293323 0.83 HRH3 (0.69) ALDH1A1SMN1; SMN2ATMKDM4EMEN1
SCHEMBL10601850 0.82 SMN1; SMN2 (0.59) ALDH1A1LMNAPOLBSMN1; SMN2MAPT
SCHEMBL10600924 0.81 SMN1; SMN2 (0.61) ALDH1A1LMNAPOLBSMN1; SMN2MAPT
SCHEMBL10604885 0.81 SMN1; SMN2 (0.57) ALDH1A1LMNAPOLBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257350-A1 COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION THE CLEVELAND CLINIC FOUNDATION 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257350-A1 COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION CHAT, DCX, GAP43 ALDH1A1 611/4885LMNA 2149/4885POLB 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback